原发性高血压病人血管内皮损伤与凝血纤溶指标变化关系被引量：4

CHANGES OF ENDOTHELIUM DYSFUNCTION, BLOOD COAGULATION AND FIBRINOLYSIS INDEXES IN ESSENTIAL HYPERTENSION

导出

摘要 ①目的探讨内皮损伤的分子标志物与原发性高血压血栓性疾病发生的关系。②方法应用酶联免疫吸附法(ELISA),测定98例不同分级原发性高血压病人和36例健康对照者血浆血栓调节蛋白(TM)、血管性血友病因子(VWF)、纤溶酶原激活剂抑制物1(PAI1)的水平,并进行比较。③结果与正常对照组比较,1、2、3级高血压组VWF、PAI1水平显著增高,2、3级高血压组TM水平显著增高,差异均有显著性(F=4.39～6.66,q=2.93～7.06,P<0.05);不同分级之间比较,2、3级高血压组TM、VWF、PAI1水平显著高于1级组(q=2.82～6.37,P<0.05)。④结论原发性高血压病人存在的血管内皮损伤、抗凝作用减弱、血小板黏附与聚集、纤溶活性下降,可能是其并发心、脑血管血栓性疾病的原因之一。 Objective To discuss the relationship between the molecular markers of endothelial dysfunction and the complications of thromboembolism in essential hypertension（EH）. Methods The plasma concentration of TM, VWF, and PAI-1 were measured by ELISA method in 98 patients with essential hypertension and 36 healthy controls. Results Compared with healthy controls, the levels of plasma VWF, and PAI-1 were significantly higher in EH patients with grade 1,2,3 group （F=4.39-6.66,q=2.93-7.06,P〈0. 05）. Compared with grade 1 group, the levels of plasma TM, VWF, and PAI-1 were significantly higher in EH patients with grade 2,3 group （q=2.82-6.37,P〈0.05）. Conclusion Essential hypertension patients have endothelium dysfunction, anticoagulant reduction, platelet activation and impaired fibrinolysis, which may be the pathogenesis of complications such as ischemic stroke and heart attacks.

作者马宏张七一

机构地区青岛市市立医院干部保健科

出处《齐鲁医学杂志》 2005年第6期485-486,488,共3页 Medical Journal of Qilu

关键词血栓调节蛋白 von WILLEBRAND因子纤溶酶原激活剂抑制物-1 高血压 thrombomodulin von Willebrand factor plasminogen activator inhibitor type 1 hypertension

分类号 R544.1 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献4

1Sadler JE. Thrombomodulin structure and function [J].Thromb Haemost, 1997,78:392.
2Galatius SS, Wroblewski H, Vibeke BS, et al. Endothelin and Von Willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: different stimuli for release before and after heart transplantation [J]. Am Heart J,1999,137:549.
3Kloczko J,Naqvi T,Waite M, et al. Von Willebrand factor antigen and fibronection in essential hypertension [J]. Thromb Res, 1995,79:331.
4Blann AD, Dobrotova M, Kubisz P, et al. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis [J]. Thromb Haemost, 1995,74(2):626.